Latest & greatest articles for fatigue

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fatigue or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fatigue and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fatigue

221. The effectiveness of interventions used in the treatment/management of chronic fatigue syndrome and/or myalgic encephalomyelitis in adults and children

The effectiveness of interventions used in the treatment/management of chronic fatigue syndrome and/or myalgic encephalomyelitis in adults and children The effectiveness of interventions used in the treatment/management of chronic fatigue syndrome and/or myalgic encephalomyelitis in adults and children The effectiveness of interventions used in the treatment/management of chronic fatigue syndrome and/or myalgic encephalomyelitis in adults and children NHS Centre for Reviews and Dissemination (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. The effectiveness of interventions used in the treatment/management of chronic fatigue syndrome and/or myalgic encephalomyelitis in adults and children. University of York. CRD Report 22. 2002 Authors' objectives The aim of this study was to assess

2002 Health Technology Assessment (HTA) Database.

222. Systematic review of the current literature related to disability and chronic fatigue syndrome

Systematic review of the current literature related to disability and chronic fatigue syndrome Systematic review of the current literature related to disability and chronic fatigue syndrome Systematic review of the current literature related to disability and chronic fatigue syndrome Ross S D, Levine C, Ganz N, Frame D, Estok R, Stone L, Ludensky V Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Ross S D, Levine C, Ganz N, Frame D, Estok R, Stone L, Ludensky V. Systematic review of the current literature related to disability and chronic fatigue syndrome. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 66. 2002 Authors' objectives The objective of this evidence report was to perform a systematic review of the published literature to provide the Social Security Administration (SSA

2002 Health Technology Assessment (HTA) Database.

223. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction

Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction Ko D T, Hebert P R, Coffey C S, Sedrakyan A, Curtis J P, Krumholz H M Authors' objectives To determine the association of beta-blockers with depressive symptoms, fatigue and sexual dysfunction by performing a quantitative review of randomised trials (...) and had a diagnosis of myocardial infarction, hypertension or congestive heart failure. Outcomes assessed in the review The outcomes to be assessed were the frequency of depressive symptoms, fatigue or sexual dysfunction. The withdrawal of medication for depressive symptoms, fatigue or sexual dysfunction was also assessed. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many of the reviewers performed

2002 DARE.

224. Symptom Management in Cancer: Pain, Depression, and Fatigue

Symptom Management in Cancer: Pain, Depression, and Fatigue NIH State-of-the-Science Statement on Symptom Management in Cancer: Pain, Depression, and Fatigue NIH Consensus and State-of-the-Science Statements Volume 19, Number 4 July 15–17, 2002 NATIONAL INSTITUTES OF HEALTH Office of the Director About the NIH Consensus Development Program NIH Consensus Development and State-of-the-Science Conferences are convened to evaluate the available scientific evidence on a given biomedi­ cal or public (...) , and fatigue. NIH Consens State Sci Statements. 2002 Jul 15–17; 19(4) 1—29. Publications Ordering Information NIH Consensus Statements, State-of-the-Science Statements, and Technol­ ogy Assessment Statements and related materials are available by writing to the NIH Consensus Development Program Information Center, P.O. Box 2577, Kensington, MD 20891; by calling toll free 1-888-NIH-CONSENSUS (888-644-2667); or by visiting the NIH Consensus Development Program home page at http://consensus.nih.gov

2002 NIH Consensus Statements

225. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. (Abstract)

Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Certain infections can trigger chronic fatigue syndromes (CFS) in a minority of people infected, but the reason is unknown. We describe some factors that predict or are associated with prolonged fatigue after infectious mononucleosis and contrast these factors with those that predicted mood disorders after the same infection.We prospectively studied a cohort of 250 primary-care (...) patients with infectious mononucleosis or ordinary upper-respiratory-tract infections until 6 months after clinical onset. We sought predictors of both acute and chronic fatigue syndromes and mood disorders from clinical, laboratory, and psychosocial measures.An empirically defined fatigue syndrome 6 months after onset, which excluded comorbid psychiatric disorders, was most reliably predicted by a positive Monospot test at onset (odds ratio 2.1 [95% CI 1.4-3.3]) and lower physical fitness (0.35 [0.15

2001 Lancet

226. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. (Abstract)

Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Cognitive behaviour therapy (CBT) seems a promising treatment for chronic fatigue syndrome (CFS), but the applicability of this treatment outside specialised settings has been questioned. We compared CBT with guided support groups and the natural course in a randomised trial at three centres.Of 476 patients diagnosed with CFS, 278 were eligible and willing to take part. 93 were randomly assigned (...) CBT (administered by 13 therapists recently trained in this technique for CFS), 94 were assigned the support-group approach, and 91 the control natural course. Multidimensional assessments were done at baseline, 8 months, and 14 months. The primary outcome variables were fatigue severity (on the checklist individual strength) and functional impairment (on the sickness impact profile) at 8 and 14 months. Data were analysed by intention to treat.241 patients had complete data (83 CBT, 80 support

2001 Lancet Controlled trial quality: predicted high

227. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. (Abstract)

Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. Patients with chronic fatigue syndrome (CFS) are more likely than healthy persons to develop neurally mediated hypotension (NMH) in response to prolonged orthostatic stress.To examine the efficacy of fludrocortisone acetate as monotherapy for adults with both CFS and NMH.Randomized, double-blind, placebo-controlled trial conducted between March 1996 and February 1999.Two

2001 JAMA Controlled trial quality: predicted high

228. Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome. Full Text available with Trip Pro

Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome. To assess the efficacy of an educational intervention explaining symptoms to encourage graded exercise in patients with chronic fatigue syndrome.Randomised controlled trial.Chronic fatigue clinic and infectious diseases outpatient clinic.148 consecutively referred patients fulfilling Oxford criteria for chronic fatigue syndrome.Patients randomised to the control group received standardised (...) medical care. Patients randomised to intervention received two individual treatment sessions and two telephone follow up calls, supported by a comprehensive educational pack, describing the role of disrupted physiological regulation in fatigue symptoms and encouraging home based graded exercise. The minimum intervention group had no further treatment, but the telephone intervention group received an additional seven follow up calls and the maximum intervention group an additional seven face to face

2001 BMJ Controlled trial quality: uncertain

229. Chronic fatigue syndrome - exercise and cognitive behaviour therapies

Chronic fatigue syndrome - exercise and cognitive behaviour therapies Chronic fatigue syndrome - exercise and cognitive behaviour therapies Chronic fatigue syndrome - exercise and cognitive behaviour therapies Bernath V Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bernath V. Chronic fatigue syndrome - exercise and cognitive behaviour therapies. Clayton (...) , Victoria: Centre for Clinical Effectiveness (CCE) 2001: 11 Authors' objectives This aim of this critical appraisal was to assess whether exercise or cognitive behaviour therapies are effective in reducing symptoms of chronic fatigue syndrome in hospitalised patients or patients visiting outpatient clinics. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cognitive Therapy; Exercise Therapy; Fatigue Syndrome, Chronic Language Published English Country of organisation Australia

2001 Health Technology Assessment (HTA) Database.

230. Chronic fatigue syndrome

Chronic fatigue syndrome Chronic fatigue syndrome Chronic fatigue syndrome Dolors Estrada M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dolors Estrada M. Chronic fatigue syndrome. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN01/2001. 2001 Authors' objectives To assess (...) the available evidence on the effectiveness of treatments for chronic fatigue syndrome (CFS). Authors' conclusions Based on evidence from randomised controlled trials, only cognitive behavioural therapy has been shown to benefit (improve) physical function in adults with CFS in ambulatory regimen, and on an individualised basis when compared to routine medical treatment. The lack of studies or the contradictory results in other treatments considered (antiviral, immunological, active agents on the central

2001 Health Technology Assessment (HTA) Database.

231. Defining and managing chronic fatigue syndrome

Defining and managing chronic fatigue syndrome Defining and managing chronic fatigue syndrome Defining and managing chronic fatigue syndrome Agency for Healthcare Research and Quality Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Agency for Healthcare Research and Quality. Defining and managing chronic fatigue syndrome. Rockville (...) : Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 42. 2001 Authors' objectives Objectives of this evidence report are to summarize research evidence regarding the case definitions, prevalence, natural history and therapy of chronic fatigue syndrome (CFS). Authors' conclusions Existing case definitions for CFS appear to characterize a group of people with prolonged fatigue and impaired ability to function. The validity and superiority of any particular case

2001 Health Technology Assessment (HTA) Database.

232. Defining and managing chronic fatigue syndrome

Defining and managing chronic fatigue syndrome Defining and managing chronic fatigue syndrome Defining and managing chronic fatigue syndrome Mulrow C D, Ramirez G, Cornell J E, Allsup K Authors' objectives The review covered four research objectives: (1) to find the existing case definitions of chronic fatigue syndrome (CFS) in adults; (2) what case definitions have been substantiated and/or validated in adults; (3) the prevalence and natural history of CFS in adults; and (4) whether (...) there is evidence to show that particular treatments improve clinical symptoms of CFS when compared to placebo, no therapy, or each other. Only the fourth objective is addressed in this abstract of the review. Searching MEDLINE, the Cochrane Library, PsycINFO (from 1980 to July 2000), EMBASE (from 1988 to 1993 and 1998 to 2000) and the Journal of Chronic Fatigue Syndrome (from 1996 to 2000) were searched using an extensive list of search terms, which were listed in full in the report. In addition, Internet

2001 DARE.

233. Cognitive behaviour therapy for adults with chronic fatigue syndrome. (Abstract)

Cognitive behaviour therapy for adults with chronic fatigue syndrome. 1. To systematically review all randomised controlled trials of cognitive-behaviour therapy (CBT) for adults with chronic fatigue syndrome (CFS); 2. To test the hypothesis that CBT is more effective than orthodox medical management or other interventions in adults with CFS.1. Electronic searching of bibliographic databases, including Medline, PsycLIT, Biological Abstracts, Embase, SIGLE, Index to Theses, Index to Scientific (...) appears to be an effective and acceptable treatment for adult out-patients with chronic fatigue syndrome. CFS is a common and disabling disorder. Its sufferers deserve the medical profession to be more aware of the potential of this therapy to bring lasting functional benefit, and health service managers to increase its availability. Further research is needed in this important area. Trials should conform to accepted standards of reporting and methodology. The effectiveness of CBT in more and less

2000 Cochrane

234. Treatments for fatigue in multiple sclerosis: a rapid and systematic review

Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Branas P, Jordan R, Fry-Smith A, Burls A, Hyde C Authors' objectives To review evidence of the effects and overall effectiveness of promising interventions in the treatment of fatigue in multiple sclerosis (MS). Searching The authors searched MEDLINE (1966 to December (...) or an alternative intervention were included in the review. Specific interventions included in the review Amantadine and pemoline. Participants included in the review Patients diagnosed with clinically definite multiple sclerosis (MS) without restriction by age, sex, or category of MS. Presence of fatigue at baseline was not a necessary criterion. Clinically definite MS was defined as: two attacks and clinical evidence of two lesions (or paraclinical evidence of the second). Outcomes assessed in the review

2000 DARE.

235. Treatments for fatigue in multiple sclerosis: a rapid and systematic review

Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Branas P, Jordan R, Fry-Smith A, Burls A, Hyde C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Branas P (...) , Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technology Assessment 2000; 4(27): 1-61 Authors' objectives - To identify current treatments for fatigue in MS and their evidence-base. - To systematically review the evidence for those treatments that have been investigated in more than one rigorous study, in order to determine their effectiveness and cost-effectiveness. Authors' conclusions There is insufficient evidence

2000 Health Technology Assessment (HTA) Database.

236. Treatments for fatigue in multiple sclerosis: a rapid and systematic review Full Text available with Trip Pro

Treatments for fatigue in multiple sclerosis: a rapid and systematic review Treatments for fatigue in multiple sclerosis: a rapid and systematic review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

2000 NIHR HTA programme

237. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. (Abstract)

Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. A woman with chronic hepatitis C and profound fatigue became symptomfree when treated long-term with ondansetron 4 mg twice daily. Altered central serotoninergic neurotransmission may contribute to fatigue complicating chronic liver disease.

1999 Lancet Controlled trial quality: uncertain

238. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. (Abstract)

Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Reports of mild hypocortisolism in chronic fatigue syndrome led us to postulate that low-dose hydrocortisone therapy may be an effective treatment.In a randomised crossover trial, we screened 218 patients with chronic fatigue. 32 patients met our strict criteria for chronic fatigue syndrome without co-morbid psychiatric disorder. The eligible patients received consecutive treatment with low-dose hydrocortisone (5 (...) mg or 10 mg daily) for 1 month and placebo for 1 month; the order of treatment was randomly assigned. Analysis was by intention to treat.None of the patients dropped out. Compared with the baseline self-reported fatigue scores (mean 25.1 points), the score fell by 7.2 points for patients on hydrocortisone and by 3.3 points for those on placebo (paired difference in mean scores 4.5 points [95% CI 1.2-7.7], p=0.009). In nine (28%) of the 32 patients on hydrocortisone, fatigue scores reached

1999 Lancet Controlled trial quality: predicted high

239. Iron therapy in chronically fatigued, nonanemic women: a double-blind study. (Abstract)

Iron therapy in chronically fatigued, nonanemic women: a double-blind study. 13800263 1998 11 01 2018 12 01 0003-4819 52 1960 Feb Annals of internal medicine Ann. Intern. Med. Iron therapy in chronically fatigued, nonanemic women: a double-blind study. 378-94 BEUTLER E E LARSH S E SE GURNEY C W CW eng Journal Article United States Ann Intern Med 0372351 0003-4819 E1UOL152H7 Iron OM Double-Blind Method Fatigue therapy Female Humans Iron therapy FATIGUE/therapy IRON/therapy 1960 2 1 1960 2 1 0 1

1998 Annals of Internal Medicine Controlled trial quality: predicted high

240. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. (Abstract)

Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. Chronic fatigue syndrome (CFS) is associated with a dysregulated hypothalamic-pituitary adrenal axis and hypocortisolemia.To evaluate the efficacy and safety of low-dose oral hydrocortisone as a treatment for CFS.A randomized, placebo-controlled, double-blind therapeutic trial, conducted between 1992 and 1996.A single-center study in a tertiary care research institution.A total of 56 women and 14

1998 JAMA Controlled trial quality: predicted high